HGEN - Humanigen, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
+0.1920 (+20.69%)
As of 3:40PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.9280
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Avg. Volume6,660
Market Cap123.241M
Beta (3Y Monthly)5.29
PE Ratio (TTM)N/A
EPS (TTM)-0.18
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Humanigen Study of GM-CSF Neutralization With CAR-T Therapy Selected for Front Cover of Current Edition of ‘blood’®, The Official Journal of the American Society of Hematology (ASH)

    Enhanced anti-tumor activity, improved overall survival, and an exponential increase in CAR-T cell proliferation was observed with GM-CSF neutralizationLenzilumab (an.

  • GlobeNewswire2 months ago

    Humanigen Announces Publication Demonstrating EphA3 Receptor as an Attractive Antibody Target for Brain Cancer and Other Solid Tumor Therapy in the Journal ‘Cancers’

    Humanigen, Inc., (HGEN) (“Humanigen”), a biopharmaceutical company developing its portfolio of Humaneered® monoclonal antibodies focused on CAR-T optimization and immuno-oncology announced that new research was published in the December issue of the journal Cancers demonstrating that the EphA3 receptor, the novel target for the company’s proprietary monoclonal antibody ifabotuzumab, is an attractive tumor-specific target for glioblastoma multiforme (GBM) therapy.

  • GlobeNewswire3 months ago

    Lenzilumab Data Presented in Oral Presentation at the American Society of Hematology (ASH)

    Humanigen, Inc., (HGEN) (“Humanigen”), a biopharmaceutical company focused on the development of its proprietary Humaneered® monoclonal antibodies to improve the safety and efficacy of chimeric antigen receptor T cell (CAR-T) therapy, announced that final results from the xenograft study of lenzilumab, a first-in-class anti-GM-CSF monoclonal antibody, were presented in the oral plenary session at the 2018 Annual Meeting of the American Society of Hematology, on Monday, December 3rd, 2018 by Rosalie Sterner from Mayo Clinic. The principal investigator for the study was Saad Kenderian, M.B., Ch.B., Mayo Clinic hematologist.   The abstract entitled “GM-CSF Blockade during Chimeric Antigen Receptor T Cell Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance Their Effector Functions” was published as a first edition paper by ‘blood’® in the November 21, 2018 edition and is available online at http://www.bloodjournal.org/content/early/2018/11/21/blood-2018-10-881722.  The full abstract with corresponding figures is available for review at: https://ash.confex.com/ash/2018/webprogram/Paper111766.html.

  • Lupagen & Humanigen to explore point-of-care CAR-T therapy
    PR Newswire9 months ago

    Lupagen & Humanigen to explore point-of-care CAR-T therapy

    DALLAS , May 22, 2018 /PRNewswire/ -- Lupagen, Inc. ( www.lupagen.com ), a medical device company developing first-in-class cell and gene therapy delivery technologies for CAR-T, gene editing and immunotherapy ...